Synthesis of 18F-labeled Novel Phosphonium cations as PET Myocardial Perfusion Imaging Agents: Pilot Imaging Studies

다국어 초록 (Multilingual Abstract)

The development of myocardial perfusion imaging (MPI) agents has been motivated because coronary artery disease has been one of the leading causes of death worldwide since the 1960s. Several positron emission tomography (PET) MPI agents were developed, and 18F-labeled phosphonium cations were reported actively among them. In this study, we synthesized novel 18F-labeled phosphonium cations, (5-[18F]fluoropentyl)diphenyl( pyridin-2-yl)phosphonium and (2-(2-[18F]fluoroethoxy)ethyl)diphenyl(pyridin-2-yl)phosphonium, and evaluated potential as MPI agents. Two labeled compounds were synthesized via nucleophilic substitution reactions of 18F-fluoride with the appropriate tosylate precursor in the presence of Kryptofix 2.2.2 and K2CO3.
MicroPET studies were performed in normal rats to evaluate in vivo distribution of radiolabeled phosphonium cations for 60 min. The radiolabeled compounds were synthesized with 5%–10% yield. The radiochemical purity of labeled compounds was > 98% by analytical HPLC, and the specific activity was > 11.8 GBq/μmol.
The result of microPET studies of these labeled compounds in rats showed intense uptake in the myocardium at 30 and 60 min. The results suggest that these 18F-labeled novel phosphonium cations would have potential as promising candidates for myocardial perfusion imaging.

참고문헌 (Reference)

1 Fukuda H, "Use of 11C-triphenylmethylphosphonium for the evaluation of membrane potential in the heart by positron-emission tomography" 11 : 478-483, 1986

2 Gibbons RJ, "The quantification of infarct size" 44 : 1533-1542, 2004

3 Min JJ, "Tetraphenylphosphonium as a novel molecular probe for imaging tumors" 45 : 636-643, 2004

4 Z C, "Synthesis of(4-[18F]fluorophenyl)triphenylphosphonium as a potential imaging agent for mitochondrial dysfunction" 48 : 131-137, 2005

5 Kim DY, "Synthesis of [18F]-labeled(6-fluorohexyl)triphenylphosphonium cation as a potential agent for myocardial imaging using positron emission tomography" 23 : 431-437, 2012

6 Kim DY, "Synthesis of [18F]-labeled(2-(2-fluoroethoxy)ethyl)tris(4-methoxyphenyl)phosphonium cation as a potential agent for positron emission tomography myocardial imaging" 39 : 1093-1098, 2012

7 Kim DY, "Synthesis of [18F]-labeled(2-(2-fluoroethoxy)ethyl)triphenylphosphonium cation as a potential agent for myocardial imaging using positron emission tomography" 22 : 319-322, 2012

8 Higuchi T, "Stable delineation of the ischemic area by the PET perfusion tracer 18F-fluorobenzyl triphenyl phosphonium after transient coronary occlusion" 52 : 965-969, 2011

9 Murphy MP, "Selective targeting of bioactive compounds to mitochondria" 15 : 326-330, 1997

10 Jacobson O, "Rat imaging and in vivo stability studies using [11C]-dimethyl-diphenyl ammonium, a candidate agent for PET-myocardial perfusion imaging" 40 : 967-973, 2013

11 Ravert HT, "Radiosynthesis of 3-[18F]fluoropropyl and 4-[18F]fluorobenzyl triarylphosphonium ions" 47 : 469-476, 2004

12 Kim DY, "Radiosynthesis and evaluation of 18F-labeled aliphatic phosphonium cations as a myocardial imaging agent for positron emission tomography" 36 : 747-754, 2015

13 김동연 ; 민정준, "Radiolabeled Phosphonium Salts as Mitochondrial Voltage Sensors for Positron Emission Tomography Myocardial Imaging Agents" 대한핵의학회 50 (50): 185-195, 2016

14 표아영 ; 송보름 ; 김희정 ; 김동연, "Radiolabeled Benzamide Derivatives for Development of Malignant Melanoma Imaging Agents" 대한방사성의약품학회 8 (8): 25-31, 2022

15 Knuuti J, "Positron emission tomography and molecular imaging" 94 : 360-367, 2008

16 Klein R, "PET and SPECT tracers for myocardial perfusion imaging" 50 : 208-218, 2020

17 Ilovich O, "Novel and simple carbon-11-labeled ammonium salts as PET agents for myocardial perfusion imaging" 13 : 128-139, 2011

18 Kroemer G, "Mitochondrial control of apoptosis : an introduction" 304 : 433-435, 2003

19 Yalamanchili P, "Mechanism of uptake and retention of F-18 BMS-747158-02 in cardiomyocytes : a novel PET myocardial imaging agent" 14 : 782-788, 2007

20 Ross MF, "Lipophilic triphenylphosphonium cations as tools in mitochondrial bioenergetics and free radical biology" 70 : 222-230, 2005

21 Marshall RC, "Kinetic analysis of 18F-fluorodihydrorotenone as a deposited myocardial flow tracer : comparison to 201Tl" 45 : 1950-1959, 2004

22 Marshall RC, "Kinetic analysis of 125I-iodorotenone as a deposited myocardial flow tracer : comparison with 99mTc-sestamibi" 42 : 272-281, 2001

23 Kim DY, "Evaluation of a mitochondrial voltage sensor, (18F-fluoropentyl)triphenylphosphonium cation, in a rat myocardial infarction model" 53 : 1779-1785, 2012

24 김동연 ; 조상건 ; 범희승, "Emerging Tracers for Nuclear Cardiac PET Imaging" 대한핵의학회 52 (52): 266-278, 2018

25 Ohira H, "Current and future clinical applications of cardiac positron emission tomography" 77 : 836-848, 2013

26 Kim DY, "Comparison of 18F-labeled fluoroalkylphosphonium cations with 13N-NH3 for PET myocardial perfusion imaging" 56 : 1581-1586, 2015

27 Madar I, "Characterization of uptake of the new PET imaging compound 18F-fluorobenzyl triphenyl phosphonium in dog myocardium" 47 : 1359-1366, 2006

28 Madar I, "Characterization of membrane potential-dependent uptake of the novel PET tracer 18F-fluorobenzyl triphenylphosphonium cation" 34 : 2057-2065, 2007

29 Madar I, "Assessment of severity of coronary artery stenosis in a canine model using the PET agent 18F-fluorobenzyl triphenyl phosphonium : comparison with 99mTc-tetrofosmin" 48 : 1021-1030, 2007

30 Small GR, "Advances in cardiac SPECT and PET imaging: Overcoming the challenges to reduce radiation exposure and improve accuracy" 29 : 275-284, 2013